Human Pathology · 2017 · 61 citations · 29 references
MedicineImmunologyOncologyCancer ImmunologyMonoclonal AntibodiesTumor ImmunologyAntibody CharacterizationCancer ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy For Breast CancerTumor AntigensTumor-associated AntigensAntibodiesPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-1 InhibitionProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 Targeting
29
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations
Medicine, Oncology, Pharmacology +12